文献速递妇科肿瘤乳腺癌

低肿瘤突变负荷(TMB)的TP53突变癌症免疫原性差异:一项关于TP53突变子宫内膜癌、卵巢癌和三阴性乳腺癌的研究

Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.
PubMed 文献 · Eur J Cancer · 2025-02-20

研究比较了606例TP53突变子宫内膜癌(EC)、高级别浆液性卵巢癌(HGSOC)和三阴性乳腺癌(TNBC)患者中TMB与肿瘤免疫微环境(TIME)的差异。结果显示EC的TMB最低(中位1.27 Mut/Mb,p<0.001),但EC的免疫抑制特征较少,而HGSOC和TNBC呈免疫敌对环境,可能解释EC对免疫检查点抑制剂(ICIs)的独特反应。

要点

  • EC的TMB最低(中位1.27 Mut/Mb,p<0.001),但免疫抑制特征少于HGSOC和TNBC
  • 高TMB与三种肿瘤的临床结局改善均显著相关,EC中无进展生存期(PFS)区分度最好(HR:0.52)
  • EC中免疫激活的mDCs较HGSOC更突出(p<0.001),免疫抑制调节因子FOXP3、C1QA、XBP1水平均低于HGSOC和TNBC(p<0.001)

核心结论

  • EC表现出较少的免疫抑制特征,尽管TMB极低,但预期对ICIs有更高的应答可能性,而HGSOC和TNBC呈免疫敌对的TIME。

研究设计与样本

  • 从606例患有EC、HGSOC或TNBC的患者中获取「癌症基因组图谱」数据,比较临床结局、TMB和TIME详细组成,使用Kruskal-Wallis检验后行Pearson相关性分析,采用Kaplan-Meier和Cox回归分析评估预后价值。

主要发现

  • 三种TP53突变肿瘤的TMB均极低,EC最低(中位1.27 Mut/Mb;p<0.001)。
  • 高TMB与每种肿瘤的临床结局改善均显著相关,EC中PFS区分度最好(HR:0.52)。
  • 与EC相比,HGSOC和TNBC中免疫抑制性调节性T细胞更高(p<0.001),HGSOC中M2样巨噬细胞更高(p<0.001)。
  • EC中免疫激活的mDCs较HGSOC更突出(p<0.001)。
  • 免疫抑制调节因子FOXP3、C1QA和XBP1区分度最高,其在EC中的水平均低于HGSOC和TNBC(p<0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore why in large phase III randomized clinical trials TP53-mutated (TP53mut) endometrial cancer (EC) was the only tumor showing survival benefit to immune checkpoint inhibitors (ICIs) added to chemotherapy when compared with other low TMB TP53mut cancers, such as high-grade serous ovarian (HGSOC) and triple-negative breast cancer (TNBC). EXPERIMENTAL DESIGN: From 606 patients with one of the three mentioned cancers, "The Cancer Genome Atlas" data on clinical outcome, TMB and detailed composition of the tumor immune-microenvironment (TIME) (immune infiltrating cells, cytokines, and other immune-modulators) were compared using the Kruskal-Wallis test, followed by Pearson correlation. Prognostic value of studied variables was assessed by Kaplan-Meier and Cox-regression analyses. RESULTS: TMB was very low in all three TP53mut entities, being lowest in EC (median: 1.27 Mut/Mb; p < 0.001). Interestingly, high TMB was significantly associated with improved clinical outcome in every entity, whereby best discrimination for PFS was found in EC (HR: 0.52). Compared to EC, immune-suppressing regulatory T-cells were higher in HGSOC and TNBC (p < 0.001) and M2-like macrophages higher in HGSOC (p < 0.001). In contrast, immune-activating mDCs were more prominent in EC than in HGSOC (p < 0.001). Differential modulator expression analyses revealed highest discrimination for the immune-inhibiting FOXP3, C1QA and XBP1, which all exhibited lower levels in EC compared with HGSOC and TNBC (p < 0.001). CONCLUSION: Characteristics of TIME differ substantially among the assessed entities in terms that EC exhibits fewer immunosuppressive traits, expecting a higher likelihood for responding to ICIs, despite a very low TMB, whereas HGSOC and TNBC exhibit an immune hostile TIME.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Steger K, Fiegl H, Feroz B, et al. Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer. Eur J Cancer. 2025. PMID: 39986022. doi:10.1016/j.ejca.2025.115320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。